UDP-GalNAc—Precision glycosylation, the cornerstone of the next generation of biopharmaceuticals

Uracil-5′-diphosphate-N-acetylgalactosamine (UDP-GalNAc) is an indispensable key sugar donor in the cellular glycosylation pathway and is known as the “engine of O-linked glycosylation”. It is not only a core molecule for post-translational modification of proteins in life, but also a strategic raw material for precise design and functional optimization in the fields of modern biomedicine, especially glycoprotein drugs, vaccines and antibody-drug conjugates (ADCs).

Product core information

Chemical name: Uracil-5′-bisphosphate-N-acetylgalactosamine disodium salt

Common name: UDP-N-acetylgalactosamine, UDP-GalNAc

English name: UDP-ALPHA-D-N-ACETYLGALACTOSAMINE, DISODIUM SALT

Chemical formula: C17H28N3NaO17P2

Molecular weight: 631.35 g/mol

CAS number: 108320-87-2

Structural characteristics and biological significance

UDP-GalNAc has a sophisticated structure and powerful functions:

High-energy sugar donor: As a uridine diphosphate (UDP)-activated sugar molecule, UDP-GalNAc, catalyzed by glycosyltransferase, can efficiently transfer N-acetylgalactosamine (GalNAc) groups to proteins (especially serine/threonine residues), initiating and completing O-linked glycosylation.

The "code" of cell communication: The glycosylation modification mediated by it is like giving a unique "identity code" to proteins, deeply involved in and regulating key life processes such as cell recognition, adhesion, signal transduction and immune response.

Main applications and core values

1. The engine of glycoprotein and vaccine development

Customized glycosylation: When synthesizing or recombinantly expressing therapeutic glycoproteins (such as EPO, monoclonal antibodies) in vitro, the exogenous addition of UDP-GalNAc can achieve precise control of the degree of protein glycosylation, thereby optimizing the stability, half-life and biological activity of the drug.

A powerful tool for vaccine design: For vaccines based on virus-like particles (VLPs) or recombinant proteins, specific antigenic epitopes can be "camouflaged" or "exposed" by regulating glycosylation patterns, helping to design a new generation of vaccines with stronger immunogenicity and higher specificity.

2. “Navigation Header” for Antibody-Drug Conjugates (ADCs)

Construction of site-specific ADC: GalNAc is a high-affinity ligand for the asialoglycoprotein receptor (ASGPR), which is highly expressed specifically on the surface of hepatocytes. Taking advantage of this characteristic, the GalNAc unit can be introduced into the design of ADC to achieve specific targeted delivery of drugs to the liver, providing a new solution for the treatment of liver diseases (such as liver cancer and fibrosis).

Enhanced therapeutic window: Through GalNAc-mediated targeting, it can significantly increase the enrichment of ADC in the lesion site and reduce off-target toxicity to normal tissues, thus greatly improving the therapeutic index and safety of the drug.

3. Tools for cutting-edge research and diagnostic development

Basic research on glycobiology: UDP-GalNAc is an ideal substrate and tool for studying glycosyltransferase activity, exploring the O-glycosylation pathway and its mechanism of action in diseases (such as cancer, neurodegenerative diseases).

Biomarker Discovery: Many cancers and diseases are accompanied by abnormal O-glycosylation. UDP-GalNAc can be used to synthesize or detect specific sugar chain structures, facilitating the discovery of new disease diagnostic biomarkers and the development of detection kits.

Conclusion

Uracil-5′-bisphosphate-N-acetylgalactosamine disodium salt (UDP-GalNAc) is far more than a biochemical reagent. It is a bridge connecting genetic blueprints and protein functions, and is the key to unlocking precision medicine and the next generation of biologics. From optimizing the performance of blockbuster biopharmaceuticals, to developing innovative liver-targeted therapies, to decoding the life codes of diseases, its value is limitless.